$COO

The Cooper Companies (COO) stock rose 22.2% in three months, outperforming its industry and the S&P 500. Q2 revenue hit $1.08B, up 8%, and adjusted EPS increased 26% to $1.21. Growth was driven by contact lens demand and fertility market recovery. CooperVision maintained market leadership, while CooperSurgical showed signs of recovery. However, Asia-Pacific weakness and strategic review of CooperSurgical pose risks.

Cooper Companies (COO) develops contact lenses and surgical products through CooperVision and CooperSurgical. The stock is 24.6% below its 52-week high ($89.83) and has underperformed XLV over 3 months (+2.1% for XLV vs. -3.1% for COO) and 52 weeks (-2.8% vs. +12.3%). After Q2 2026 results on June 5, shares rose 8.6% as revenue reached $1.1B (+7.9%) and adjusted EPS was $1.21. Analysts (17) rate it “Moderate Buy” with a mean target of $81.60.

Natixis Advisors LLC increased its stake in The Cooper Companies by buying 270,476 shares in Q4, bringing holdings to 303,456 shares, according to its latest SEC 13F. The position was valued at about $24.9M (~0.15%). Separately, the article notes Cooper’s fiscal Q2 EPS of $1.21 (vs $1.10 consensus) and revenue of $1.08B, plus FY2026 EPS guidance of $4.58–$4.66.

Cooper Companies (NASDAQ:COO) reported quarterly EPS of $1.21, above the $1.10 consensus, and revenue of $1.08 billion versus $1.05 billion, according to FiscalAI. The company updated FY 2026 guidance to $4.580–$4.660 EPS. Shares rose to $62.02 midday. Analysts cited include Barclays ($103) and Goldman Sachs ($61).

CooperCompanies (COO) is set to report Q1 earnings Thursday after the bell. The company reported Q1 revenue of $1.02B, up 6.2% year over year, and met revenue expectations; it beat full-year EPS guidance, with organic revenue in line. For Q1, analysts expect 5.1% revenue growth. CooperCompanies shares are down 3.3% over a month; the average analyst price target is $88.21 vs. $59.50.

CooperCompanies (COO) is set to report Q1 earnings Thursday after the bell. The company reported Q1 revenue of $1.02B, up 6.2% year over year, meeting analyst expectations; it also beat full-year EPS guidance. For Q1, analysts expect revenue growth of 5.1% y/y. The average analyst price target is $88.21 vs. $59.50 current.

The Cooper Companies stock (COO) dropped 0.80% to $59.47 on May 13, 2026, marking a 27.4% year-to-date decline. Despite the recent dip, the company, specializing in vision care and surgical devices, maintains strong fundamentals and net margins, outperforming some competitors in the healthcare sector. Investors are watching its performance in the growing US healthcare market.

CooperCompanies (Nasdaq: COO) is a global leader in medical technology, specializing in vision care through CooperVision and women's health products via CooperSurgical. The company's core business model focuses on innovation in contact lenses and fertility solutions, with significant revenue driven by daily disposables, toric lenses, and products for IVF procedures. CooperCompanies maintains a strong competitive position by addressing growing demands in vision correction and reproductive health, particularly in North America, Europe, and Asia-Pacific.

CooperCompanies (Nasdaq: COO) announced it will report Q2 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET, with a conference call following at 5:00 PM ET. The call will discuss results and corporate developments, and can be accessed via dial-in or webcast. This announcement continues the company's regular communication cadence regarding earnings.

The Cooper Companies (US21664P1039) is poised to release its first-quarter 2026 financial results today, April 30. Investors will be scrutinizing the performance of its contact lenses (CooperVision) and women's health (CooperSurgical) segments for insights into growth, margins, and supply chain resilience. The company operates globally, with a strong presence in the U.S., and is known for its research-driven product development and strategic acquisitions in specialty healthcare.